The forefront of agriculture/medicine interactions is the use of plants to manufacture innovative medicinal products directly. An emerging biopharmaceutical industry geared toward manufacture of human monoclonal antibodies using crop plants as factories, reduces the serious manufacturing bottleneck that often currently prevents mass-scale application of antibody therapeutics from meeting clinical needs. This medical market, already valued at $4 billion a year, could be revolutionized a biotech-based production system.